分子靶向放疗增敏剂的筛选与验证
本文讨论了分子靶向放疗增敏剂临床转化不足的原因,包括临床前数据可重复性差、肿瘤基因组异质性建模不足及依赖肿瘤生长延迟而非局部控制(TCD50)终点。作者提出采用三维细胞培养高通量筛选、克隆形成实验、生物标志物验证及TCD50实验等策略以提高转化成功率。
要点
- 三维细胞培养可预测体内放疗增敏效应,如EGFR或FAK抑制增敏头颈癌。
- 高通量三维筛选应覆盖基因组特征明确的肺癌、头颈癌和胰腺癌细胞系。
- 候选药物需经克隆形成实验、TCD50实验及生物标志物验证后方可临床转化。
核心结论
- 经适当验证和生物标志物导向的靶向治疗比既往尝试更可能成功纳入难治性肿瘤的标准治疗。
研究设计与样本
- 本文为方法学论述,提出利用三维细胞培养、高通量筛选、克隆形成实验、TCD50实验及患者来源肿瘤模型等策略筛选和验证靶向放疗增敏剂。
主要发现
- 三维细胞培养成功预测了抑制EGFR或FAK信号对头颈癌的放疗增敏及KRAS致癌突变相关的放疗抵抗。
- 高通量三维筛选覆盖肺癌、头颈癌和胰腺癌的基因组特征细胞系,有望发现基因组生物标志物。
关键数值与推荐
- 筛选命中物需经克隆形成实验、加入疾病特异性化疗药、靶点/生物标志物验证及患者来源肿瘤模型整合等细化研究。
- 最有前景的药物应在异种移植模型中用临床相关分割放疗、伴或不伴相关生物标志物进行TCD50实验确认放化疗增敏活性。
临床怎么用
- 临床转化前应使用三维细胞培养高通量筛选结合生物标志物验证来优先选择靶向放疗增敏剂。
- 候选药物需在异种移植模型中用TCD50终点和临床相关分割放疗确认疗效。
局限性
- 原文未报告具体研究样本量、P值或置信区间等定量数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The development of molecular targeted drugs with radiation and chemotherapy is critically important for improving the outcomes of patients with hard-to-treat, potentially curable cancers. However, too many preclinical studies have not translated into successful radiation oncology trials. Major contributing factors to this insufficiency include poor reproducibility of preclinical data, inadequate preclinical modeling of intertumoral genomic heterogeneity that influences treatment sensitivity in the clinic, and a reliance on tumor growth delay instead of local control (TCD50) endpoints. There exists an urgent need to overcome these barriers to facilitate successful clinical translation of targeted radiosensitizers. To this end, we have used 3-dimensional (3D) cell culture assays to better model tumor behavior in vivo. Examples of successful prediction of in vivo effects with these 3D assays include radiosensitization of head and neck cancers by inhibiting epidermal growth factor receptor or focal adhesion kinase signaling, and radioresistance associated with oncogenic mutation of KRAS. To address the issue of tumor heterogeneity, we leveraged institutional resources that allow high-throughput 3D screening of radiation combinations with small-molecule inhibitors across genomically characterized cell lines from lung, head and neck, and pancreatic cancers. This high-throughput screen is expected to uncover genomic biomarkers that will inform the successful clinical translation of targeted agents from the National Cancer Institute Cancer Therapy Evaluation Program portfolio and other sources. Screening "hits" need to be subjected to refinement studies that include clonogenic assays, addition of disease-specific chemotherapeutics, target/biomarker validation, and integration of patient-derived tumor models. The chemoradiosensitizing activities of the most promising drugs should be confirmed in TCD50 assays in xenograft models with or without relevant biomarker and using clinically relevant radiation fractionation. We predict that appropriately validated and biomarker-directed targeted therapies will have a higher likelihood than past efforts of being successfully incorporated into the standard management of hard-to-treat tumors.
引用
- Willers H, Pan X, Borgeaud N, et al. Screening and Validation of Molecular Targeted Radiosensitizers. Int J Radiat Oncol Biol Phys. 2021. PMID: 34343607. doi:10.1016/j.ijrobp.2021.07.1694
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。